BERLIN — German pharmaceutical company BioNTech says it expects to receive the results of trials of its coronavirus vaccine in younger children by September.
BioNTech, which developed the first widely approved COVID-19 shot with U.S. partner Pfizer, has already submitted data from trials in children ages 12-15 to the U.S. Food and Drug Administration and plans to do so for the European Medicines Agency, which regulates drugs for use in the 27-nation European Union. .
The company said it expects results from trials in children ages 5-12 “as early as July” and in those younger than 5 in September.
BioNTech said requests for regulatory approval would depend on the results of the trials.
The company is one of the main suppliers of coronavirus vaccines in Europe and North America.
BEIJING (AP) — Genetic material collected at a Chinese market near where the first human cases of COVID-19 were identified show raccoon dog DNA comingled with the virus, adding evidence to the theory that the virus originated from animals, not from a lab, international experts say.
FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.
NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.
Explore articles from the past and connect to your heritage!
Discover the benefits of a subscription including access to exclusive content, events, and more!
Have an idea for a story, or know of an event we should cover? We want to hear about it!
The National Herald is the paper of record of the Greek Diaspora community. Through independent journalism, we bring news to generations of Greek-Americans, with stories on the individual, community and international level. Visit and support our 106 year-old sister publication Εθνικός Κήρυξ.
To purchase a gift subscription, please log out of your account, and purchase the subscription with a new email ID.
Sign up to receive our daily email news briefing.
Sign up for a subscription to The National Herald,
starting as low as $1/week.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
We use cookies on our site to personalize your experience, bring you the most relevant content, show you the most useful ads, and to help report any issues with our site. You can update your preferences at any time by visiting preferences. By selecting Accept, you consent to our use of cookies. To learn more about how your data is used, visit our cookie policy.
$1.09 USD
